Smegglutide is available in two formulations: a glucose-lowering version and a weight-loss version. These should not be mixed.

One formulation, the glucose-lowering version, is generally used clinically for overweight or obese adults with type 2 diabetes. The other formulation, the weight-loss version, is suitable for long-term weight management in adult patients based on dietary control and increased physical activity.

When using the weight-loss version of smegglutide, the initial BMI must meet the following criteria: 1. BMI ≥ 30 kg/m² (obese), can be used directly. 2. Or BMI ≥ 27 kg/m² to < 30 kg/m² (overweight) and at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. It cannot distinguish between primary and secondary obesity (such as Cushing's syndrome, pituitary adenoma), and only treats the symptoms, not the underlying cause. Weight loss needs to be combined with diet and exercise. Some patients can maintain their weight after discontinuing the medication, but long-term lifestyle intervention is required. Purchasing medication online without authorization, self-administering injections, and arbitrarily increasing dosages pose significant hidden risks: Skipping professional risk assessments and failing to screen for contraindications such as pancreatitis and thyroid disease.

Improper storage and transportation (requires a 2-8℃ cold chain) may cause the medication to denature and become ineffective.

Heart, kidney, and thyroid function must be assessed before use; do not adjust the dosage without consulting a doctor. Individuals with a history of mental illness should be monitored for depression and suicidal tendencies. Overdose requires immediate medical attention to rule out hypoglycemia and liver or kidney damage.

When used in combination with other medications, an interval of 1-2 hours should be maintained between doses (to avoid delaying gastric emptying and affecting absorption).